Navigation Links
Biologicals in Oncology Drug Pipeline Update 2013
Date:8/26/2013

NEW YORK, Aug. 26, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Biologicals in Oncology Drug Pipeline Update 2013

http://www.reportlinker.com/p0379872/Biologicals-in-Oncology-Drug-Pipeline-Update-2013.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development

This drug pipeline update covers a wide array of biological drugs, such as: antibodies,proteins, peptides, DNA, RNA and cellular therapies.

There are today 881 companies plus partners developing 1527 biological drugs in 3359 developmental projects in cancer. In addition, there are 24 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 889 drugs. Biologicals In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 604 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 566 out of the 570 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 82 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

How May Drug Pipeline Update Be of Use? * Show investors/board/management that you are right on top of drug development progress in your therapeutic area. * Find competitors, collaborations partners, M&A candidates etc. * Jump start competitive drug intellige
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Hoosier Oncology Group Selects OnCore to Support Clinical Trials Network
2. Orfit Launches Open Face Hybrid Mask For Patient Immobilization In Radiation Oncology
3. Life Technologies and RainTree Oncology Services Announce Collaboration to Bring Molecular Tumor Testing to Community Oncologists
4. Astellas Appoints New Senior Vice President of Global Oncology Development
5. Oncology remains most restrictive specialty for second year
6. Using Success & Failure Roadmap Paves the Way for Positive New Product Launches in Oncology
7. Accelovance Primed to Achieve Leadership in Oncology Clinical Trials
8. Loxo Oncology And Array BioPharma Announce License And Collaboration Agreement
9. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
10. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
11. PRISM Pharma Closes $15 million Series C Financing to Advance PRI-724 into Non-oncology Indications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015  Amgen (NASDAQ: AMGN ... quarter of 2015. Key results include: , ... quarter of 2014 to $5,370 million, with 6 ... ® (etanercept), Prolia ® (denosumab), Sensipar ... XGEVA ® (denosumab). Unfavorable changes in foreign ...
(Date:7/30/2015)... WOODCLIFF LAKE, N.J. , July 30, 2015 /PRNewswire/ ... submitted simultaneously in the United States ... (to the FDA, EMA and MHLW, respectively) for eribulin, ... sarcoma (STS) who have received prior chemotherapy for advanced ... are based on data from a pivotal global Phase ...
(Date:7/30/2015)... , July 30, 2015 Takeda ... the study to fulfill the post-marketing commitment and ... Pan European Multi-Database Bladder Cancer Risk Characterization ... matched cohort study, conducted in four European countries, ... with up to 10 years of follow-up. Findings ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 2Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 3Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 4Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 6
... Oct. 28 Horror stories related to medical equipment for ... thousands, even millions of dollars are wasted, and delays in ... www.ecri.org ), an independent nonprofit that researches the best ... equipment issues and 6 best practices to ensure a better ...
... Pharmaceuticals, Inc.® (Nasdaq GM: DUSA), a specialty pharmaceutical ... sales volumes of the Levulan® Kerastick®, an integral ... platform, surpassed one million units. , "The achievement ... U.S. and abroad continue to embrace Levulan PDT ...
Cached Medicine Technology:Is Poor Medical Equipment Planning Costing your Healthcare Project Wasted Dollars and Delays? ECRI Institute outlines best practices to ensure better outcomes 2Is Poor Medical Equipment Planning Costing your Healthcare Project Wasted Dollars and Delays? ECRI Institute outlines best practices to ensure better outcomes 3DUSA Pharmaceuticals Surpasses One Million in Cumulative Levulan(R) Kerastick(R) Sales Units 2
(Date:7/30/2015)... ... July 30, 2015 , ... World Patent ... Fine, an app invention that can help people during emergencies. , "The worldwide ... CEO and Creative Director of World Patent Marketing. "Currently, there are about 97,000 ...
(Date:7/30/2015)... , ... July 30, 2015 , ... The connection between a healthy head of hair ... The loss of a full head of hair can have a devastating impact on the ... is perceived in the work place, the consequences of hair loss are not to be ...
(Date:7/30/2015)... ... 2015 , ... Mullin/Ashley Associates, Inc. , an integrated ... the Service Industry Advertising Awards 12th annual national competition. , The awards ... University of Maryland Shore Regional Health. , A Gold Award was won by ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Orange, Riverside, Los Angeles, and San Bernardino counties, today announced that Dr. Michael ... Care Administrator. Dr. Demoratz is a strong proponent of early access to palliative ...
(Date:7/30/2015)... ... July 30, 2015 , ... OncLive®’s extensive ... UCLA’s Jonsson Comprehensive Cancer Center (JCCC) mutually agreed to collaborate on projects ... editorial and marketing groups will help spread the news about the center’s leading-edge ...
Breaking Medicine News(10 mins):Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 2Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 3Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 5Health News:New Study Shows the Link between Hair Restoration and Healthy Self-Image 2Health News:Mullin/Ashley Associates Takes Home Wins for Three Clients in the Service Industry Advertising Awards Annual Competition 2Health News:Mullin/Ashley Associates Takes Home Wins for Three Clients in the Service Industry Advertising Awards Annual Competition 3Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 2Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 3Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 3Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 4
... physicians identified six cases of accidental ingestion of wire ... paper calls attention to the need for the public and ... published in the American Journal of Roentgenology and ... Grand, M.D., a radiologist in the diagnostic imaging department at ...
... 28 (HealthDay News) -- Tourists over age 65 who visit malaria-infested ... disease than those ages 18 to 35, a new study says. ... 25,000 U.K. patients also found that the malaria death rate is ... The risk of dying from malaria, an infection carried by mosquitoes, ...
... , WEDNESDAY, March 28 (HealthDay News) -- A drink or ... in the two decades following a heart attack, a new study ... European Heart Journal , included more than 1,800 American men ... were followed for up to 20 years. During that time, 468 ...
... treated with intensity modulated radiation therapy (IMRT) instead of ... of acute or chronic toxicities, according to a study ... the official clinical practice journal of the American Society ... to determine the most effective breast cancer treatment that ...
... Salamon HealthDay Reporter , MONDAY, March 26 (HealthDay ... new study suggests. Those who spend 11 or more hours ... over the next three years regardless of how physically active ... more than 222,000 people aged 45 and older, Australian researchers ...
... 27 (HealthDay News) -- Women with ovarian cancer who ... have annual incomes of less than $35,000 are more ... Researchers found these racial and socioeconomic disparities in ... of surviving for five years after their cancer diagnosis. ...
Cached Medicine News:Health News:Rhode Island Hospital study identifies the danger of grill brushes 2Health News:Older Travelers at Much Higher Risk of Dying From Malaria 2Health News:Moderate Drinking Might Help Men Live Longer After Heart Attack 2Health News:IMRT reduces risk of side effects in breast cancer patients 2Health News:Too Much Sitting Can Kill You, Study Suggests 2Health News:Too Much Sitting Can Kill You, Study Suggests 3Health News:Black Women, Uninsured Get Worse Ovarian Cancer Care: Study 2
Intended for the quantitative determination of uric acid in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 20 mg/dL (1190 mol/L). Single vial, dry powder reagent....
... Advia Centaur delivers a new level of ... to integrate with any laboratory automation system. ... supplies. It is the only immunoassay system ... load samples; system runs without any additional ...
... fully automated, random access ... 50 assays available worldwide. ... marker, therapeutic drug, serology, ... can be performed on ...
... for small and medium volume laboratories, as ... System offers the speed, simplicity and flexibility ... Compact yet powerful, the Elecsys 1010 system ... response assays to routine testing without sacrificing ...
Medicine Products: